# Evaluation of ETC-1002 vs Placebo in Patients Receiving Ongoing Statin Therapy

Study · id `cardio:ct-nct02072161` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02072161](<https://clinicaltrials.gov/study/NCT02072161>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT02072161

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 133 participants.

## Technical summary

Registry record NCT02072161. Randomized; quadruple masking; primary purpose treatment. Start 2014-03 (registry gives no type); primary completion 2015-01 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 133 participants (enrolled count; ClinicalTrials.gov record NCT02072161, source copy `cardio:ctgov-nct02072161-2019-03-29`, retrieved 2026-10-31)
- Start date: 2014-03 (registry gives no type) (ClinicalTrials.gov record NCT02072161, source copy `cardio:ctgov-nct02072161-2019-03-29`, retrieved 2026-10-31)
- Primary completion: 2015-01 (actual) (ClinicalTrials.gov record NCT02072161, source copy `cardio:ctgov-nct02072161-2019-03-29`, retrieved 2026-10-31)
- Completion: 2015-01 (actual) (ClinicalTrials.gov record NCT02072161, source copy `cardio:ctgov-nct02072161-2019-03-29`, retrieved 2026-10-31)
- Countries: United States (ClinicalTrials.gov record NCT02072161, source copy `cardio:ctgov-nct02072161-2019-03-29`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02072161-2019-03-29`, retrieved 2026-10-31)

## The registry's words

- Brief title: Evaluation of ETC-1002 vs Placebo in Patients Receiving Ongoing Statin Therapy
- Condition: Hypercholesterolemia
- Intervention (Drug): ETC-1002
- Intervention (Drug): Placebo
- Intervention (Drug): Statin Therapy
- Lead sponsor: Esperion Therapeutics, Inc.
- Lead sponsor class: INDUSTRY
- Collaborator: Medpace, Inc.
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: High cholesterol (hypercholesterolemia) (`cardio:hypercholesterolemia`)
- Registry lists this organization as the lead sponsor: Esperion Therapeutics, Inc. (`cardio:org-esperion-therapeutics-inc`)
- Registry lists this organization as a collaborator: Medpace, Inc. (`cardio:org-medpace-inc`)

## Provenance

Content hash: 4a383ff87da275dacb5cd2968cc5d42216f72ad44ef2545ab0294511ad1a7ea6
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
